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A new adjuvant 
for the hepatitis B 
vaccine
Hepatitis B remains a serious problem 
for patients on hemodialysis. Vaccina-
tion is now the standard for patients 
planning to undergo this procedure. 
As they report in this issue, Kong et 
al. evaluated the immune response to 
the hepatitis B vaccine by measuring 
antibody persistence and anamnestic 
response following a booster dose of the 
vaccine. A new adjuvant (AS04) pro-
duced an earlier antibody response than 
the standard adjuvant, which caused 
higher titers that lasted for longer peri-
ods. Also, the decline in antibody tit-
ers following vaccination was slower 
in the new adjuvant compared with 
the old one. Following a booster shot 
42 months after the initial vaccina-
tion, titers increased 64-fold in those 
immunized with the standard vaccine, 
whereas it increased almost 200-fold in 
those immunized with the AS04 adju-
vant. The new adjuvant appeared to be 
well tolerated. These results provide an 
important development in improving 
the immune response to the hepatitis B 
vaccine. See page 835.
Dendritic cells and 
hypoxia
Recently, a number of groups have iden-
tiﬁed dendritic cells in the kidney as a 
new antigen-presenting cellular compart-
ment. It is now well known that ischemia 
is associated with invasion of bone mar-
row-derived cells, and that inﬂammation 
is a signiﬁcant part of the morbidity of 
this disease. Given this knowledge, Rama 
et al. studied the role of hypoxia in mat-
uration of local kidney-based dendritic 
cells. In response to antigen stimulation, 
these cells differentiated and became 
fully active dendritic cells that presented 
antigen. When the cells differentiated 
in response to hypoxia, they expressed 
hypoxia-inducible factor-1α and its tar-
get genes. Interestingly, in mice subjected 
to ischemia–reperfusion injury, the den-
dritic cells became diﬀerentiated. These 
studies may begin to explain the inﬂam-
mation so often seen in ischemic injury. 
See page 863.
Biomarkers for acute 
kidney injury
The traditional diagnosis of acute kidney 
injury relies on a rise in serum creatinine, 
but this measurement is not sensitive 
enough for detection, especially early in 
the course of the disease. Han et al. now 
evaluate a number of potential urinary 
biomarkers of acute kidney injury, such 
as matrix metalloproteinase-9 (MMP-9), 
N-acetyl-β-D-glucosaminidase (NAG), 
and kidney injury molecule-1 (KIM-1). 
The authors used urine from normal 
adults and those with various kinds 
of acute kidney injury, as well as from 
children undergoing cardiopulmonary 
bypass. The levels of these markers were 
measured, and the patients were divided 
into categories of acute kidney injury 
based on the rise of serum creatinine 
2 days after baseline. The urine levels 
were measured three times in the ﬁrst 
36 hours. The combined measurements 
of all three markers provided a perfect 
predictive score. In this case-controlled 
trial, KIM-1 was a better predictor than 
NAG, and both predictors combined 
did not improve the predictive power. 
This study provides an excellent initial 
investigation in the burgeoning ﬁeld of 
biomarkers for early detection of acute 
kidney injury. See page 816.
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